BMP7

(redirected from Bmp-7)

BMP7

A gene on chromosome 20q13 that encodes bone morphogenetic protein-7, which plays a key role in cartilage formation, osteoblast differentiation, renal development and repair, and induces the production of SMAD1.
References in periodicals archive ?
Other claims provide for growth factors such as BMP-2, BMP-4, BMP-6, BMP-7, transforming growth factor (TGF-?
Following the reverse merger, Ember Therapeutics will continue to develop BMP-7, which achieved promising results in a Phase II(a) trial, which evaluated the local administration of BMP-7 in patients with osteoarthritis of the knee.
BMP-2, BMP-4, BMP-7, and BMP-9 expression was significantly increased at the messenger RNA level in quadriceps of mice that underwent SCI (Figures 6-7).
There are two BMPs clinically available: BMP-7 (also known as osteogenic protein-1 or OP-1) supplied by Stryker UK, which uses a bovine collagen carrier in granular form (OP-1 Putty in the US and Osigraft [R] in the UK), and rhBMP-2 supplied by Wyeth Research Ltd, which uses a collagen sponge carrier (InFUSE in the US and InductOs in the UK).
PF also suppressed epithelial-mesenchymal transition (EMT) by down-regulating TGF-[beta]1 expression and maintaining BMP-7 mRNA expression, and inhibited Smad 2/3 activation in fibrotic kidneys induced by UUO.
Due to the short half-life of BMP-7, high doses are required to induce bone healing.
the therapeutic drug development company, has released favorable findings surrounding CURIS BMP-7 protein drug candidate.
After 4 weeks, new bone occupied approximately 90% of the defects that received the BMP-7 transduced cells," Krebsbach reported.
Although the virus can't replicate, it infects the cells and induces some of them to mass-produce BMP-7 and others to take on the role of bone-building cells.
Currently, two of these proteins BMP-2 and BMP-7, are approved for clinical use in non-union, tibial fractures and spinal fusion procedures.
Human recombinant BMP-7 has previously been used in reconstructive bone applications in over 40,000 patients.
SVA uses the known 3D structure of the clinically validated BMP-7 protein and its corresponding cell surface receptors, along with the known activities of the other BMPs, to generate a rich set of active compounds.